Pacifica Partners Inc. 购买了百时美施贵宝（纽约证券交易所代码：BMY）的6,120股股票-手机新浪网

Pacifica Partners Inc. increased its position in shares of Bristol-Myers Squibb (NYSE:BMY – Get Rating) by 14.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 47,601 shares of the biopharmaceutical company's stock after purchasing an additional 6,120 shares during the quarter. Bristol-Myers Squibb accounts for approximately 2.3% of Pacifica Partners Inc.'s investment portfolio, making the stock its 11th largest position. Pacifica Partners Inc.'s holdings in Bristol-Myers Squibb were worth $3,460,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of BMY. New Millennium Group LLC acquired a new position in shares of Bristol-Myers Squibb in the second quarter valued at approximately $31,000. My Personal CFO LLC acquired a new stake in Bristol-Myers Squibb during the 4th quarter valued at approximately $35,000. Clear Investment Research LLC acquired a new stake in Bristol-Myers Squibb during the 3rd quarter valued at approximately $36,000. Western Pacific Wealth Management LP increased its position in Bristol-Myers Squibb by 878.6% during the 3rd quarter. Western Pacific Wealth Management LP now owns 548 shares of the biopharmaceutical company's stock valued at $38,000 after purchasing an additional 492 shares during the period. Finally, McClarren Financial Advisors Inc. acquired a new stake in Bristol-Myers Squibb during the 3rd quarter valued at approximately $41,000. Institutional investors own 75.51% of the company's stock.

Get

Bristol-Myers Squibb

alerts:

Bristol-Myers Squibb Stock Performance

NYSE:BMY opened at $66.98 on Friday. The business has a 50 day moving average of $70.62 and a 200 day moving average of $72.85. The company has a market capitalization of $140.58 billion, a price-to-earnings ratio of 22.71, a PEG ratio of 1.46 and a beta of 0.46. Bristol-Myers Squibb has a 1-year low of $65.28 and a 1-year high of $81.43. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.25 and a quick ratio of 1.14.

Bristol-Myers Squibb (NYSE:BMY – Get Rating) last announced its quarterly earnings results on Thursday, February 2nd. The biopharmaceutical company reported $1.82 EPS for the quarter, topping analysts' consensus estimates of $1.71 by $0.11. Bristol-Myers Squibb had a return on equity of 51.60% and a net margin of 13.71%. The business had revenue of $11.41 billion for the quarter, compared to analysts' expectations of $11.20 billion. During the same period in the previous year, the firm earned $1.83 EPS. The business's quarterly revenue was down 4.8% on a year-over-year basis. On average, sell-side analysts predict that Bristol-Myers Squibb will post 8.06 earnings per share for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, May 1st. Stockholders of record on Monday, April 10th will be issued a dividend of $0.57 per share. This represents a $2.28 dividend on an annualized basis and a dividend yield of 3.40%. The ex-dividend date of this dividend is Thursday, April 6th. Bristol-Myers Squibb's payout ratio is currently 77.29%.

Wall Street Analyst Weigh In

BMY has been the topic of a number of recent research reports. Atlantic Securities increased their target price on Bristol-Myers Squibb from $88.00 to $90.00 and gave the stock an "overweight" rating in a report on Friday, February 3rd. Morgan Stanley raised their price objective on Bristol-Myers Squibb from $60.00 to $62.00 and gave the company an "underweight" rating in a research note on Friday, February 3rd. Cantor Fitzgerald initiated coverage on Bristol-Myers Squibb in a research note on Tuesday, January 17th. They set an "overweight" rating and a $95.00 price objective on the stock. Jefferies Financial Group initiated coverage on Bristol-Myers Squibb in a research note on Monday, March 6th. They set a "hold" rating and a $62.00 price objective on the stock. Finally, Wells Fargo & Company raised their price objective on Bristol-Myers Squibb from $70.00 to $78.00 and gave the company an "equal weight" rating in a research note on Tuesday, January 3rd. One investment analyst has rated the stock with a sell rating, seven have given a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $79.69.

Insider Activity

In related news, EVP Ann Powell sold 11,183 shares of the company's stock in a transaction on Monday, February 6th. The stock was sold at an average price of $74.69, for a total transaction of $835,258.27. Following the completion of the sale, the executive vice president now owns 23,043 shares in the company, valued at $1,721,081.67. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In related news, EVP Ann Powell sold 11,183 shares of the company's stock in a transaction on Monday, February 6th. The stock was sold at an average price of $74.69, for a total transaction of $835,258.27. Following the completion of the sale, the executive vice president now owns 23,043 shares in the company, valued at $1,721,081.67. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Giovanni Caforio sold 240,000 shares of the company's stock in a transaction on Monday, February 6th. The shares were sold at an average price of $74.65, for a total value of $17,916,000.00. Following the sale, the chief executive officer now owns 236,104 shares of the company's stock, valued at approximately $17,625,163.60. The disclosure for this sale can be found here. Corporate insiders own 0.09% of the company's stock.

Bristol-Myers Squibb Profile

(Get Rating)

Bristol Myers Squibb Co engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.